Teva Expects To Benefit From Consolidation Driven By "Authorized" Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Generic firms with smaller pipelines will feel pressure from authorized generics, CEO Makov says. Teva will not pursue a Mylan/King type of acquisition to boost its brand business because "we are doing very well in generics," the exec says.
You may also be interested in...
“Authorized” Generics Fight Moves To Capitol Hill, FTC
Mylan plans to meet with Hill staffers, members of Congress to lay the groundwork for legislation against “authorized” generic deals. The company is leading efforts of generic firms who are trying to persuade FTC that authorized generics do not save consumers money and result in fewer patent challenges.
“Authorized” Generics Fight Moves To Capitol Hill, FTC
Mylan plans to meet with Hill staffers, members of Congress to lay the groundwork for legislation against “authorized” generic deals. The company is leading efforts of generic firms who are trying to persuade FTC that authorized generics do not save consumers money and result in fewer patent challenges.
King To Set Aside Additional $65 Mil. To Settle SEC/OIG Investigation
The company’s Medicaid underpayment liability is approximately $130 mil. King says its wholesaler inventory levels have begun to normalize with 2.4 months of Rx demand across its four key products.